David Ricks

Under his leadership, Lilly's market capitalization has grown from approximately $80 billion to over $800 billion, making it the world's most valuable pharmaceutical company — surpassing longtime leaders like Johnson & Johnson, Roche, and Pfizer. The driver is the GLP-1 receptor agonist revolution. Lilly's tirzepatide molecule, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, represents a once-in-a-generation therapeutic breakthrough. GLP-1 drugs don't just lower blood sugar — they produce dramatic weight loss of 15-25% of body weight, with emerging data showing cardiovascular, kidney, and liver benefits. The addressable market is potentially hundreds of millions of patients worldwide. Ricks made the strategic bet on GLP-1 early, investing heavily in manufacturing capacity when competitors hesitated. Lilly has committed over $20 billion in manufacturing expansion to meet demand that continues to exceed supply. This manufacturing buildout represents both Lilly's competitive moat and its biggest execution risk. Beyond GLP-1, Ricks has built a formidable pipeline including donanemab (Alzheimer's), mirikizumab (Crohn's disease), and next-generation diabetes therapies. He has navigated the political controversy around drug pricing, with GLP-1 drugs facing scrutiny over their $1,000+/month list prices. The key question for investors is whether Lilly can maintain its manufacturing and competitive lead as Novo Nordisk's Ozempic/Wegovy and new entrants challenge for market share in what may become the largest drug category in history.